COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
Pentixapharm Holding AG receives FDA approval for Phase III study on [68Ga]Ga-PentixaFor in Primary Aldosteronism, targeting billion-dollar revenue potential in underserved market -
-
COMMUNIQUÉ DE PRESSE
MHM Corporate: announces the availability of its general meeting documentation
MHM Corporate announces availability of general meeting documentation for June 30, 2026, including agenda on website. Topics: financial statements, director appointments, compensation policies, and more -
-
COMMUNIQUÉ DE PRESSE
Nebius launches Physical AI Living Lab for UK and European robotics startups built with NVIDIA technologies
Nebius launches Physical AI Living Lab for UK and European robotics startups built with NVIDIA technologies. Program to accelerate real-world deployment and remove infrastructure barriers -
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm receives FDA clearance for Phase 3 PANDA study of novel cardiovascular diagnostic program targeting resistant hypertension and primary aldosteronism -
COMMUNIQUÉ DE PRESSE
THX Pharma, Biocodex et la Fondation Beyond Batten Disease s'engagent aux côtés de la communauté CLN3 à l'occasion de la Journée internationale de sensibilisation à la maladie de Batten
THX Pharma, Biocodex et la Fondation Beyond Batten Disease (BBDF) sont conjointement Sponsors Platinum de la BDSRA Conference 2026 pour la maladie de Batten. Annonce du programme Batten-1 et de son étude pivot internationale de phase 3 -
COMMUNIQUÉ DE PRESSE
THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
Join THX Pharma, Biocodex, and BBDF as Platinum Sponsors at the 2026 BDSRA Family Conference to provide an update on the Batten-1 program and Phase 3 study for CLN3 Batten disease
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
